•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
ACADIA Pharmaceuticals (ACAD) Gets a Buy from RBC Capital
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Cantor picks 14 undervalued biotech stocks worth a second look
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.